EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Drugs repurposing in the experimental models of Alzheimer’s disease

Sheer A Joodi, Weam W Ibrahim, Mahmoud M Khattab

Inflammopharmacology · 2025-01 · 33 (1) · 195-214

DOI: 10.1007/s10787-024-01608-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Inflammopharmacology, online erschienen am 03.01.2025. Verfasst von Sheer A Joodi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, ElKasr Elaini Street, Cairo, 11562, Egypt. sheeralaaa@gmail.com. Hauptthemen laut MEDLINE: Alzheimer Disease, Drug Repositioning. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cairo University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The currently approved drugs for Alzheimer’s disease (AD) are only for symptomatic treatment in the early stages of the disease but they could not halt the neurodegeneration, additionally, the safety profile of the recently developed immunotherapy is a big issue. This review aims to explain the importance of the drugs repurposing technique and strategy to develop therapy for AD. We illustrated the biological alterations in the pathophysiology of AD including the amyloid pathology, the Tau pathology, oxidative stress, mitochondrial dysfunction, neuroinflammation, glutamate-mediated excitotoxicity, insulin signaling impairment, wingless-related integration site/ β -catenin signaling, and autophagy. Additionally, we demonstrated the different repurposed drugs in the experimental models of AD including the anti-inflammatory, anti-hypertensive, anti-diabetic, antiepileptic, antidepressant and anticancer drugs. Further, we showed the pipeline and FDA approved drugs for AD. The repurposed drugs have a promising therapeutic activity against AD, confirming the value of the drugs repurposing technique to elucidate curative therapy for AD. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseDrug RepositioningHumansAnimalsDisease Models, AnimalOxidative Stress

Stichwörter der Autor:innen

Alzheimer’s diseaseAnd GSK-3βAβ42NF-κβNrf2P38-MAPKmTOR

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, ElKasr Elaini Street, Cairo, 11562, Egypt. sheeralaaa@gmail.com.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, ElKasr Elaini Street, Cairo, 11562, Egypt.

Förderung

  • Cairo University

Zitieren

APA

Joodi, S. A., Ibrahim, W. W., & Khattab, M. M. (2025). Drugs repurposing in the experimental models of Alzheimer’s disease. Inflammopharmacology, 33(1), 195-214. https://doi.org/10.1007/s10787-024-01608-7

Vancouver

Joodi SA, Ibrahim WW, Khattab MM. Drugs repurposing in the experimental models of Alzheimer’s disease. Inflammopharmacology. 2025;33(1):195-214. doi:10.1007/s10787-024-01608-7

BibTeX
@article{Joodi2025,
  author = {Joodi, Sheer A and Ibrahim, Weam W and Khattab, Mahmoud M},
  title = {Drugs repurposing in the experimental models of Alzheimer’s disease},
  journal = {Inflammopharmacology},
  year = {2025},
  volume = {33},
  number = {1},
  pages = {195--214},
  doi = {10.1007/s10787-024-01608-7}
}
Kostenlos starten →